Biolegend, 502511, APC anti-human IFN-γ Antibody
25tests
Catalog Number: 502511
Send an RFQ.
Category
| Verified Reactivity | Human |
|---|---|
| Reported Reactivity | Chimpanzee, Baboon, Cynomolgus, Rhesus |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Immunogen | Partially purified, native human IFN-γ |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA) |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | ICFC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. |
| Excitation Laser | Red Laser (633 nm) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended. |
| Application References(PubMed link indicates BioLegend citation) | Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut) Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut) Sester M, et al. 2002. J. Virol. 76:3748. (ICFC) Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC) Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA) Chen H, et al. 2005. J. Immunol. 175:591. (ICFC) Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC) Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC) |
|---|
| Product Citations | Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed Shao L, et al. 2021. Cell Death Discov. 7:145. PubMed Li M, et al. 2021. J Clin Invest. 131:. PubMed Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed Swadling L, et al. 2022. Nature. 601:110. PubMed McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed Peng W, et al. 2023. Cells. 12: . PubMed Cheng H, et al. 2023. Nat Metab. 5:314. PubMed Veatch JR, et al. 2022. Cancer Cell. 40:393. PubMed Goetzmann J, et al. 2014. Proc Natl Acad Sci U S A. 111:8873. PubMed Wang H, et al. 2022. Front Immunol. 13:852436. PubMed Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed Devalraju KP, et al. 2021. PLoS One. 16:e0257185. PubMed Chandran A, et al. 2022. Cell Rep Med. 3:100557. PubMed Su W, et al. 2022. Front Immunol. 13:952338. PubMed Pandey A, et al. 2020. Nat Commun. 3.392361111. PubMed Norian L, et al. 2009. Cancer Res. 69:3086. PubMed Harshe RP, et al. 2020. Nat Commun. 11:5894. PubMed Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed Longhi M, et al. 2014. PLoS One. 9:87956. PubMed Evans RDR, et al. 2020. Nat Commun. 3.491666667. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Cai J, et al. 2021. eLife. 10:00. PubMed Baban B, et al. 2021. JCI Insight. 6:00. PubMed Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed Draganov DD, et al. 2019. J Transl Med. 17:100. PubMed Port JR, et al. 2020. J Virol. 94:. PubMed Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed Guo S, et al. 2021. Stem Cells Int. 2021:9989790. PubMed Zhang X, et al. 2017. J Immunol. 10.4049/jimmunol.1602183. PubMed Du Q, et al. 2018. J Immunol. 201:533. PubMed Ge C, et al. 2020. Cell Reports. 29(13):4236-4244.e3.. PubMed Liu W, et al. 2022. Bio Protoc. 12:e4285. PubMed Roybal KT et al. 2016. Cell. 167(2):419-432 . PubMed Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Pahl JHW, et al. 2018. Cancer Immunol Res. 0.609027778. PubMed Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed Wang Y, et al. 2021. Cell Reports. 36(6):109516. PubMed Tian X, et al. 2015. J Immunol. 194:3873. PubMed Yang C, et al. 2019. Nat Commun. 10:3931. PubMed Shen C, et al. 2021. BMC Med. 19:283. PubMed Tesch S, et al. 2020. Sci Rep. 10:21312. PubMed |
|---|
| RRID | AB_315236 (BioLegend Cat. No. 502511) AB_315237 (BioLegend Cat. No. 502512) |
|---|
| Structure | Cytokine; dimer; 20-25 kD (Mammalian) |
|---|
| Bioactivity | Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC |
|---|
| Cell Sources | CD8+ and CD4+ T cells, NK cells |
|---|
| Cell Targets | T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts |
|---|
| Receptors | IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1) |
|---|
| Cell Type | Tregs |
|---|
| Biology Area | Cell Biology, Immunology, Neuroinflammation, Neuroscience |
|---|
| Molecular Family | Cytokines/Chemokines |
|---|
| Antigen References | 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151. |
|---|
| Regulation | Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2 |
|---|
| Gene ID | 3458 |
|---|
| UniProt | View information about IFN-gamma on UniProt.org |
|---|
| Clone | 4S.B3 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma |
|---|
| Isotype | Mouse IgG1, κ |
|---|